Titanium mesh covered with biocompatible polypropylene film for covering and protecting bone grafts/biomaterials and process for obtaining same
US-2024398571-A1 · Dec 5, 2024 · US
US2017296365A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017296365-A1 |
| Application number | US-201715429339-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 10, 2017 |
| Priority date | Nov 17, 2010 |
| Publication date | Oct 19, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments are directed to radiopaque implantable structures (e.g., stents) formed of cobalt-based alloys that comprise cobalt, chromium and one or more platinum group metals, refractory metals, precious metals, or combinations thereof. Platinum group metals include platinum, palladium, ruthenium, rhodium, osmium, and iridium. Refractory metals include zirconium, niobium, rhodium, molybdenum, hafnium, tantalum, tungsten, rhenium, and precious metals include silver and gold. In one embodiment, the one or more included platinum group or refractory metals substitute at least partially for nickel, such that the alloy exhibits reduced nickel content, or is substantially nickel free. The stents exhibit improved radiopacity as compared to similar alloys including greater amounts of nickel.
Opening claim text (preview).
1 . A radiopaque stent, comprising: a cylindrical main body comprising a cobalt-based alloy including cobalt, chromium, an austenitic stabilizer for cobalt including a combination of manganese and nickel, the nickel content being less than that included in L-605 alloy (10 weight percent), the cobalt-based alloy further comprising one or more platinum group metals or precious metals selected from the group of platinum, palladium, rhodium, iridium, osmium, ruthenium, silver and gold; wherein the cobalt-based alloy comprises from 31 weight percent to 51 weight percent cobalt, from 15 weight percent to 20 weight percent chromium, from 8 weight percent to 30 weight percent of the one or more platinum group metals or precious metals; wherein the cobalt-based alloy includes up to 8 weight percent nickel, up to 20 weight percent manganese, a combined weight percentage of manganese and nickel being up to 25 weight percent, the cobalt-based alloy comprising no more than about 20 percent by weight iron. 2 . The radiopaque stent of claim 1 , wherein the cobalt-based alloy includes from 5.8 weight percent to 7.1 weight percent nickel and includes a combined weight percentage of manganese and nickel that is from 7.7 weight percent to 9.7 weight percent. 3 . The radiopaque stent of claim 1 , wherein the cobalt-based alloy has a relative radiopacity from 4.6 barnes/cm 3 to 6.5 barnes/cm 3 . 4 . The radiopaque stent of claim 1 , wherein the cobalt-based alloy includes 5 weight percent to 8 weight percent nickel. 5 . The radiopaque stent of claim 1 , wherein the cobalt-based alloy includes from 1 to 5 weight percent manganese. 6 . The radiopaque stent of claim 1 , wherein the cobalt-based alloy includes a combined weight percentage of manganese and nickel from 7 weight percent to 10 weight percent. 7 . The radiopaque stent of claim 1 , wherein the cobalt-based alloy includes no more than about 4 percent by weight iron. 8 . The radiopaque stent of claim 1 , wherein the platinum group metal or precious metal comprises at least one of platinum or palladium. 9 . The radiopaque stent of claim 1 , wherein the platinum group metal or precious metal comprises both platinum and palladium. 10 . The radiopaque stent of claim 1 , wherein the alloy further comprises tungsten. 11 . The radiopaque stent of claim 1 , wherein the alloy further comprises up to 15 weight percent tungsten. 12 . The radiopaque stent of claim 1 , wherein an entirety of the stent is formed from the cobalt-based alloy. 13 . The radiopaque stent of claim 12 , wherein the cobalt-based alloy includes from 5.8 weight percent to 7.1 weight percent nickel and includes a combined weight percentage of manganese and nickel that is from 7.7 weight percent to 9.7 weight percent. 14 . The radiopaque stent of claim 12 , wherein the cobalt-based alloy has a relative radiopacity from 4.6 barnes/cm 3 to 6.5 barnes/cm 3 . 15 . The radiopaque stent of claim 12 , wherein the platinum group metal or precious metal comprises at least one of platinum or palladium. 16 . The radiopaque stent of claim 12 , wherein the platinum group metal or precious metal comprises both platinum and palladium. 17 . The radiopaque stent of claim 12 , wherein the alloy further comprises tungsten. 18 . The radiopaque stent of claim 12 , wherein the alloy further comprises up to 15 weight percent tungsten. 19 . A radiopaque stent, comprising: a cylindrical main body comprising a cobalt-based alloy including cobalt, chromium, an austenitic stabilizer for cobalt including a combination of manganese and nickel, the nickel content being less than that included in L-605 alloy (10 weight percent), the cobalt-based alloy further comprising one or more platinum group metals or precious metals selected from the group consisting of platinum, palladium, rhodium, iridium, osmium, ruthenium, silver and gold; wherein the cobalt-based alloy comprises from 31 weight percent to 51 weight percent cobalt, from 15 weight percent to 20 weight percent chromium, from 8 weight percent to 30 weight percent of the one or more platinum group metals or precious metals; wherein the cobalt-based alloy includes 5 weight percent to 8 weight percent nickel, from 1 weight percent to 5 weight percent manganese, a combined weight percentage of manganese and nickel being from 7 weight percent to 10 weight percent, the cobalt-based alloy comprising no more than about 4 percent by weight iron. 20 . The radiopaque stent of claim 19 , wherein: (i) the cobalt-based alloy includes from 5.8 weight percent to 7.1 weight percent nickel and includes a combined weight percentage of manganese and nickel that is from 7.7 weight percent to 9.7 weight percent; and/or (ii) wherein the cobalt-based alloy has a relative radiopacity from 4.6 barnes/cm 3 to 6.5 barnes/cm 3 .
Alloys based on rhenium or a refractory metal not mentioned in groups C22C14/00 or C22C16/00 · CPC title
based on cobalt · CPC title
Alloys based on chromium · CPC title
Materials at least partially X-ray or laser opaque · CPC title
radio-opaque, e.g. radio-opaque markers · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.